Dr. Cameron’s article argues that the widely cited Klempner trials have limited generalizability beyond the select group of patients with characteristics like those in the trials and that generalizing the results may limit treatment options for people with chronic Lyme disease.
Forwarded from Dan Cameron:
My published critique of the Klempner et al trials in the journal Epidemiologic Perspectives & Innovations has already made the top 10 accessed article for the last 30 days. I need your help to make the critique their top accessed article for the year or for all time.
I would be most appreciative if you or any of your friends would access the “Generalizability in two clinical trials of Lyme disease” and click full text.